Our results show that PAPD5 catalyzes the polyadenylation of different types of RNA substrates in vitro. Interestingly, PAPD5 is active without a protein cofactor, whereas its yeast homolog Trf4p is the catalytic subunit of a bipartite poly (A) polymerase in which a separate RNA-binding subunit is needed for activity.

PAPD5 is one of the seven members of the family of noncanonical poly(A) polymerases in human cells. PAPD5 was shown to polyadenylate aberrant pre-ribosomal RNAs in vivo, similar to degradation-mediating polyadenylation by the noncanonical poly(A) polymerase Trf4p in yeast.

2020年6月4日 · We show that pharmacologic PAPD5 inhibition reverses TERC oligoadenylation and increases TERC in human cell lines, primary cells and induced pluripotent stem cells (iPSCs) from DC patients, and CRISPR/Cas9-engineered PARN -deficient primary human hematopoietic stem and progenitor cells (HSPCs).

The role of PAPD5 and PAPD7 in HBV replication was confirmed by oligonucleotide-mediated knockdown studies that phenocopied the result seen with RG7834-treated HBV-infected hepatocytes. The greatest effect on HBV gene expression was seen when PAPD5 and PAPD7 mRNAs were simultaneously knocked down, suggesting that the two cellular proteins play ...

2023年1月14日 · 厦门特宝生物工程股份有限公司研发的在研乙肝创新药物 AK0706， 靶点为PAPD5/7抑制剂，最近获得我国食药监批准针对乙肝表面抗原（HBsAg）持续阳性的HBV感染治疗开展临床试验。 作用机理方面，根据特宝生物公告描述，AK0706（片剂）是全新结构的二氢异喹啉类化合物，是高度选择性的PAPD5/7抑制剂，可显著调降乙肝表面抗原的水平，而乙肝表面抗原水平的抑制有可能打破宿主对乙肝病毒的免疫耐受，重新恢复宿主对HBV的免疫应答，拟用于 …

2020年4月21日 · 哈佛干细胞研究所Suneet Agarwal研究组的一项工作开发出了一种PAPD5小分子抑制剂，可用于恢复病人干细胞的端粒酶活性。 该研究于2020年4月21日在线发表在《细胞—干细胞》上。 研究人员报道了PAPD5的小分子抑制剂，该抑制剂在体外、干细胞模型和体内能够恢复端粒活性。 PAPD5是一种非经典聚合酶，可寡聚腺苷酸化并使端粒酶RNA组分（TERC）不稳定。 研究人员鉴定到了BCH001，这是一种特异的PAPD5抑制剂，可在先天性角化病（DC）患者 …

2014年8月5日 · PAPD5 prolongs the life of the mRNA encoding tumor suppressor TP53 by polyadenylation. By adenylating miR-21+C and thus inducing its degradation by PARN, PAPD5 prevents the oncomiR from repressing other tumor suppressors.

2020年4月22日 · 哈佛干细胞研究所Suneet Agarwal研究组 的一项工作开发出了一种PAPD5小分子抑制剂，可用于恢复病人干细胞的端粒酶活性。 该研究于2020年4月21日在线发表在 《细胞—干细胞》 上。

2020年6月4日 · PAPD5 is a non-canonical polymerase that oligoadenylates and destabilizes telomerase RNA component (TERC). We identified BCH001, a specific PAPD5 inhibitor that restored telomerase activity and telomere length in DC patient induced pluripotent stem cells.

Noncanonical poly (A) polymerases PAPD5 and PAPD7 (PAPD5/7) stabilize hepatitis B virus (HBV) RNA via the interaction with the viral posttranscriptional regulatory element (PRE), representing new antiviral targets to control HBV RNA metabolism, hepatitis B surface antigen (HBsAg) production, and viral replication.